Product logins

Find logins to all Clarivate products below.


Blog: Biopharma

Here you will find relevant articles and insight into all Clarivate related products and news.

The competitive signals hiding in plain sight for biopharma The competitive signals hiding in plain sight for biopharma
Blog May 8, 2026
The competitive signals hiding in plain sight for biopharma
Biopharma Business Development Clinical trials
Five lessons learned deploying agentic AI in the life sciences Five lessons learned deploying agentic AI in the life sciences
Blog April 30, 2026
Five lessons learned deploying agentic AI in the life sciences
AI
Target selection and safety assessment: Navigating early decisions that shape drug development Target selection and safety assessment: Navigating early decisions that shape drug development
Blog March 27, 2026
Target selection and safety assessment: Navigating early decisions that shape drug development
Development Pharma Regulatory
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
Blog March 26, 2026
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
GLP-1 Metabolic
Why longevity might be biopharma's next big thing: The science and business converge Why longevity might be biopharma's next big thing: The science and business converge
Blog March 2, 2026
Why longevity might be biopharma's next big thing: The science and business converge
Gerontology
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Biotech Clinical trials
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
FDA Regulatory Safety

Biopharma

NICE’s new Innovative Licensing and Access Pathway - how pharma can use it to accelerate market access NICE’s new Innovative Licensing and Access Pathway - how pharma can use it to accelerate market access
Blog February 23, 2021
NICE’s new Innovative Licensing and Access Pathway - how pharma can use it to accelerate market access
How the pandemic has impacted the Federal Health Insurance Exchange in the U.S. How the pandemic has impacted the Federal Health Insurance Exchange in the U.S.
Blog February 23, 2021
How the pandemic has impacted the Federal Health Insurance Exchange in the U.S.
Blog February 15, 2021
Mainland China’s anticipated biosimilar boom – potential and key drivers of the market
Making research easier for everyone: Literature search management and sharing on Dialog Making research easier for everyone: Literature search management and sharing on Dialog
Blog February 12, 2021
Making research easier for everyone: Literature search management and sharing on Dialog
Formulary exclusion strategies promote cost savings amid pandemic Formulary exclusion strategies promote cost savings amid pandemic
Blog February 9, 2021
Formulary exclusion strategies promote cost savings amid pandemic
Blog January 29, 2021
Retail giant Walmart enters the U.S. health insurance sector with Medicare plan play
Regulatory response to the COVID-19 pandemic: Fast tracking therapeutics Regulatory response to the COVID-19 pandemic: Fast tracking therapeutics
Blog January 29, 2021
Regulatory response to the COVID-19 pandemic: Fast tracking therapeutics
Regulatory response to the COVID-19 pandemic: Prevention via non-pharmaceutical intervention Regulatory response to the COVID-19 pandemic: Prevention via non-pharmaceutical intervention
Blog January 29, 2021
Regulatory response to the COVID-19 pandemic: Prevention via non-pharmaceutical intervention
Regulatory response to the COVID-19 pandemic: Careful planning to minimize disruptions Regulatory response to the COVID-19 pandemic: Careful planning to minimize disruptions
Blog January 29, 2021
Regulatory response to the COVID-19 pandemic: Careful planning to minimize disruptions
2019 PBM trend: Specialty sector at center stage 2019 PBM trend: Specialty sector at center stage
Blog January 29, 2021
2019 PBM trend: Specialty sector at center stage